Anti-Human CSF1R Recombinant Antibody (Emactuzumab) (CAT#: TAB-H23)

Figure 1 CSF-1R blockade increases the expression of intratumoural type I IFN signalling in patients with cancer treated with emactuzumab and is essential for the therapeutic synergy of cisplatin + anti-CSF-1R in the KEP mouse model a, Kaplan–Meier tumour-specific survival curves of KEP mice treated with cisplatin + control Ab, cisplatin + anti-CSF-1R, cisplatin + anti-IFNAR1 (n = 15 animals) or cisplatin + anti-CSF-1R + anti-IFNAR1 (n = 21 animals).

Cisplatin + anti-CSF-1R versus cisplatin + anti-CSF-1R + anti-IFNAR1: P = 0.0064 (two-tailed log-rank test). b, log2 ratio of intratumoural expression levels of 28 type I ISGs in emactuzumab (anti-CSF-1R)-treated patients (n = 31 patients) normalized against the pre-treatment expression levels. c, Box plots of the expression level of the 11 statistically significant upregulated type I ISGs in tumours of emactuzumab-treated patients (data from b, indicated by asterisks). Expression levels in the pre-treatment (baseline) tumour biopsies are compared to on-treatment (emactuzumab) biopsies. The top-most line is the maximum, the top of the box is the third quartile, the centre line is the median, the bottom of the box is the first quartile and the bottom-most line is the minimum. RPKM, reads per kilobase of exon per million mapped reads. The P values were determined by a two-tailed Student's t-test.

Salvagno, C., Ciampricotti, M., Tuit, S., Hau, C. S., Coffelt, S. B., Kersten, K.,... & Ooi, C. H. (2019). Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nature cell biology.

Figure 1 Anti-Human CSF1R Antibody (TAB-H23) in WB

Western blot analysis of TAB-H23 was performed with CSF1R Protein, Human, Recombinant.

TAB-H23 incubation concentration: 2ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane 1: Reducing Antigen (0.2μg)
Lane 2: Reducing Antigen (0.4μg)
Lane 3: Reducing Antigen (0.6μg)

Figure 2 Anti-Human CSF1R Antibody (TAB-H23) in ELISA

ELISA analysis of TAB-H23 was performed by coating with CSF1R Protein, Human, Recombinant.

The secondary antibody: HRP-Anti-Human IgG (H+L)